How this fund's holdings score on the six lenses, weighted by holding weight — plus what the manager is actively buying and selling. A transparency roll-up of the stock atom — descriptive, not a forecast of outperformance.
What's a “leader”? A holding that ranks in the top two deciles (D9 / D10) of its size cohort on BOTH active conviction lenses — Technical and Flow. Leadership-breadth is the share of the fund's weight sitting in those leaders.
Risk & return
Compound returns and the risk taken to earn them, from the fund's own NAV history.
| Sector | 11 Jul | 18 Jul | 25 Jul | 24 Aug | 28 Aug | 04 Sep | Δ |
|---|---|---|---|---|---|---|---|
| Pharma | 50.4 | 50.4 | 50.4 | 49.6 | 49.6 | 49.6 | -0.9 |
| Healthcare | 41.6 | 41.6 | 41.6 | 41.6 | 41.6 | 41.6 | +0.0 |
| Chemicals | 4.2 | 4.2 | 4.2 | 5.8 | 5.8 | 5.8 | +1.6 |
| FMCG | 1.2 | 1.2 | 1.2 | 1.2 | 1.2 | 1.2 | -0.1 |
| Unclassified | · | · | · | 1.0 | 1.0 | 1.0 | 0.0 |
Glass box
Click a lens to expand its holdings, ranked by contribution (weight × decile); each name links to its own evidence. Descriptive, not a forecast.
—
—
| Symbol | Sector | Weight | Tch | Fnd | Cat | Flw | Val | Lead | RS 3M |
|---|---|---|---|---|---|---|---|---|---|
| SUNPHARMA | Pharma | 8.59% | 7 | 8 | 7 | 8 | 5 | — | +1.5% |
| DIVISLAB | Pharma | 6.36% | 9 | 8 | 1 | 4 | 1 | — | +38.4% |
| HCG | Healthcare | 5.85% | 7 | 2 | 6 | 7 | 2 | — | +5.1% |
| ABBOTINDIA | Pharma | 5.63% | 3 | 9 | — | 6 | 8 | — | -3.8% |
| RAINBOW | Healthcare | 4.90% | 10 | 7 | 4 | 3 | 4 | — | +5.0% |
| GLAXO | Healthcare | 4.66% | 8 | 7 | 2 | 8 | 4 | — | +31.0% |
| CIPLA | Pharma | 4.53% | 4 | 3 | 6 | 4 | 7 | — | -3.9% |
| DRREDDY | Pharma | 4.25% | 2 | 2 | 6 | 10 | 9 | — | -14.7% |
| MAXHEALTH | Healthcare | 4.07% | 1 | 9 | 6 | 5 | 6 | — | -6.0% |
| APOLLOHOSP | Healthcare | 3.90% | 9 | 5 | 5 | 2 | 2 | — | +0.4% |
| BAYERCROP | Chemicals | 3.26% | 2 | 4 | — | 2 | 8 | — | -11.4% |
| FORTIS | Healthcare | 3.12% | 4 | 8 | 5 | 5 | 6 | — | -12.4% |
| PFIZER | Healthcare | 3.06% | 5 | 7 | 1 | 8 | 7 | — | -2.9% |
| MANKIND | Pharma | 3.02% | 4 | 8 | 9 | 3 | 5 | — | -6.1% |
| SYNGENE | Healthcare | 2.95% | 1 | 2 | 6 | 7 | 7 | — | -17.8% |
| SAILIFE | Healthcare | 2.89% | 9 | 10 | 5 | 9 | 1 | Leader | +27.8% |
| LUPIN | Pharma | 2.64% | 3 | 10 | 10 | 7 | 9 | — | -11.1% |
| ALKEM | Pharma | 2.58% | 3 | 8 | 7 | 6 | 8 | — | -6.6% |
| PGHL | Pharma | 2.42% | 4 | 4 | 1 | 8 | 5 | — | -13.0% |
| FDC | Pharma | 2.39% | 3 | 5 | 2 | 8 | 8 | — | -14.7% |
| LALPATHLAB | Healthcare | 2.17% | 7 | 8 | 7 | 5 | 3 | — | +18.6% |
| MEDANTA | Healthcare | 2.13% | 8 | 9 | 5 | 4 | 2 | — | +13.1% |
| CONCORDBIO | Pharma | 1.91% | 8 | 4 | 2 | 5 | 3 | — | +16.2% |
| SUMICHEM | Chemicals | 1.59% | 6 | 7 | 1 | 5 | 4 | — | +1.6% |
| AJANTPHARM | Pharma | 1.53% | 8 | 10 | 1 | 3 | 3 | — | +13.9% |
| NEULANDLAB | Healthcare | 1.25% | 8 | 10 | 7 | 4 | 1 | — | +30.4% |
| GILLETTE | FMCG | 1.15% | 2 | 8 | 1 | 3 | 7 | — | -7.6% |
| METROPOLIS | Pharma | 1.12% | 8 | 9 | 6 | 7 | 1 | — | +4.7% |
| BASF | Chemicals | 0.97% | 5 | 1 | 1 | 3 | 7 | — | +9.2% |
| JUBLPHARMA | Pharma | 0.83% | 3 | 1 | 3 | 3 | 7 | — | -5.2% |
| AGARWALEYE | Healthcare | 0.67% | 8 | 5 | 8 | 1 | 3 | — | +10.3% |
| BIOCON | Pharma | 0.52% | 4 | 1 | 10 | 2 | 7 | — | -8.8% |
| SANOFI | Pharma | 0.23% | 2 | 6 | 3 | 8 | 9 | — | -5.7% |
| ANTHEM | Pharma | 0.01% | 10 | 10 | 6 | 3 | 1 | Leader | +16.3% |
Performance · 5.0y
Over the last 5.0 years ₹100 in the fund grew to ₹185 (+85%), vs ₹156 for Nifty 500 (+56%) and ₹137 for Nifty 50 (+37%). Its relative-strength line ended at 135 vs Nifty 50 and 119 vs Nifty 500 — above 100, sustained outperformance.